フルサービス コマーシャル
市場での可能性を最大限に引き出す
Underpinned by our market-leading Commercial capabilities and Kinetic™, our commercial platform that streamlines and optimizes commercialization activities, Full-Service Commercialization enables biopharmaceutical companies to leverage our vast experience, predictive insights, capabilities, global infrastructure and deep local market expertise, with the goal of scaling-up, reducing risk and getting to market faster.
製品化の成功確率を上げるお手伝いを致します。
従来、初期段階にいるバイオ医薬品企業には、最初の資産を市場に投入するためのオプションが限られていました。ほとんどの場合、規模の大きいパートナーとの取引を追求するあまり、自社資産に対する権利を失ってしまうか制限されてしまったり、あるいは多大な投資と巨大なリスクのために完全に統合されてしまったりします。
弊社のフルサービス コマーシャル ソリューションには、3つ目のオプションが用意されています。それは業界をリードする統合コマーシャル デリバリー モデルです。この製薬コマーシャル事業サービスモデルの狙いは、サイネオス・ヘルス®の既存のグローバルインフラストラクチャーと膨大な専門知識を活用して、効率性、規模、およびスピードを向上させることです。そして何よりも、このモデルを使用することで、お客様は自社資産を長期にわたり管理下に置き続けて、将来のオプションの可能性を閉ざさずに済むことができます。
See how Full-Service Commercialization helped these companies reach their potential:
Mission Accomplished
A small public specialty pharmaceutical company wanted to expand its footprint of commercial operations and launch into key European markets.
We helped build a European commercial capability via a comprehensive commercialization partnership, introducing a Commercial Leadership function to support the design and execution of the overall launch plan and integrate other services. We were able to scale quickly and establish commercial operations, designed a European launch plan and forecast and launched within three months in one EU country, with a subsequent sequenced launch through Europe, despite the ambiguities of COVID-19.
Goal Achieved
A major international R&D company, responsible for multiple blockbuster molecules where US rights had been out-licensed to top pharma companies, was looking to launch its first fully owned, fully commercialized asset into the US market.
In 12 weeks, we provided a full virtual infrastructure that included Field Teams, MSLs, Access Teams, Marketplace and Access/Pricing Consulting, Advertising, Public Relations and Medical Communications, increasing operational efficiencies through integrated Communications teams to reduce duplication in effort across promotional channels and recruiting, training and deploying sales reps, achieving an annual run rate of >$200 million.
Challenge Accepted
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for its first commercial launch.
We partnered with the commercial team to provide all commercial launch services, offering crucial global leadership that enabled the team to dynamically scale up and down to respond to changing launch timelines and to balance short- and long-term financial objectives. With a heavy emphasis on market development, we empowered the customer to be fully engaged and aligned with all communities and show an in-depth understanding of market dynamics.
綿密に調整されて実行される健全な戦略
弊社は、お客様が現在医薬品コマーシャル プロセスのどこにいるのかを正確に把握し、綿密に調整し実行できる健全な戦略を策定します。バイオ医薬品企業のコマーシャル部門でエグゼクティブ リーダーを務めてきた業界経験豊富な人材が最高の支援を提供します。
弊社は、統合ソリューションの照準を貴社の事業目標に合わせ、医薬品コマーシャル サービスの構成をカスタマイズし貴社を補えるように設計します。A Syneos Health Commercialization Lead works in close collaboration with the commercialization lead in your organization, orchestrating all outsourced activity and gaining you targeted, efficient, cost-effective access to the full breadth and depth of our resources and capabilities.
Full-Service Commercialization is the commercial concierge emerging companies need that can help reduce risk, manage costs and optimize performance. 弊社が苦労して得た知識、機敏性、および比類のない専門知識は非常に大きな力があり、拡大解釈すれば貴社のものでもあります。
More Reasons Why
For established brands: 最適なプロモーションミックスを構築して収益を最大化
医薬品ブランドが成長段階から成熟段階に進むことは、特別な課題を伴い、特別なビジネスチャンスも生み出します。The challenges can be significant, but the opportunities are, too – bolstered by HCP familiarity, the availability of data on how the product works in the real-world setting, and uptake analytics that can be leveraged to refine future strategies.
既存医薬品ブランドには、いまだ収益源となる可能性がありますが、収益効果を最大化するには、より効率的なプロモーションモデルが必要です。
We approach the promotion of established pharmaceutical brands with an innovative, modular full-service marketing solution that integrates advanced data science, digital communications and resource deployment together with your existing infrastructure to realize your established brand’s full potential.
For non-core assets: solving for unique resourcing challenges
組織のコア資産（専用インフラストラクチャや対象分野の専門家を社内に擁している優先的な治療領域の資産）と比べ、非コア資産には、投資の不足、非効率と高コスト、開発を最適化するための明確な戦略的方向性の欠如など、独自のリソーシング課題があります。
The benefits of our solution?
- Expertise in your non-core therapeutic area or category by tapping our global talent
- Full suite of product development services including Clinical Development, Medical and Commercialization
- Dedicated leadership as a single point-of-contact with your organization
- Integrated support customized to your strategic goals and timelines
- Optionality to out-license, divest or transfer infrastructure as desired
統合医薬品コマーシャル サービスを提供するという目的を持って提携し成果を実現
貴社固有の資産と企業戦略を中心に設計された統合コマーシャル ソリューションを提供します。When you work with Syneos Health, our extensive commercialization capabilities – including award-winning, full-service agency capabilities – become yours. 弊社は貴社と協力して、機敏で合理化されたパートナーシップを構築し、次のものを創ります。
- Less complexity, less risk and a clear roadmap to commercial success grounded in a precise plan for all the variables unique to your asset.
- Lower infrastructure investment and up to 20% savings by using a contract commercial model.
- The ability to scale up or down to rapidly respond to market dynamics, opportunities or challenges.
- The opportunity to expand the model across multiple assets over time, utilizing the same framework and a partner who understands your organization.
- Customized, fully integrated solutions that bring deep therapeutic expertise, novel strategy and flawless execution.
- A collaborative approach that provides unique access to data and experts to “read through the noise” in every therapeutic category.
A globalization accelerator that puts faster, smarter go-to-market optionality in your hands
Full-Service Commercialization is also the ideal solution for biopharma companies seeking to launch in new markets, where they face multiple challenges that can make or break their success including resource constraints, risk exposure, the complexity of uncharted territory, and nonalignment across siloed and divergent stakeholders. Focused on your performance, we put an unmatched suite of globalization capabilities at your disposal, from strategic planning and communications to deployment solutions.
関連コンテンツ
独自のインサイトをお探しですか？
